Dr
Paola Scifo
(Nuclear Medicine Dept, IRCCS San Raffaele Scientific Institute, Milan, Italy)
The use of simultaneous hybrid PET/MRI is highly beneficial in children as it allows for a one-stop examination that limits the scanning procedures, the need for a second sedation and also reduces the radiation dose compared to PET/CT. The attenuation correction, in the brain, is performed with Atlas, with Zero Echo Time/Ultrashort Echo Time (ZTE/UTE) sequences or, more recently, with Deep Learning-based methods. In pediatric patients, and in particular in oncological pediatric studies where tumor resection may occur, the size and the abnormal shape of the head maybe critical for a good attenuation correction. In this work, we have compared the two Atlas and ZTE attenuation correction methodologies in a group of treated pediatric patients with brain tumors who underwent 11C-Methionine PET/MRI scans. This preliminary work shows that the use of ZTE or Atlas for the generation of ACmaps can modify the SUVs of the study but the differences in the values are very small. The DICE indexes calculated between lesions VOIs are high. Finally, it should be noticed that some of the patients of our sample have external ventricular drain catheter valves that generate artifacts. In these cases, interestingly, both ZTE and Atlas show bulk of signals but ACmapAtlas has smaller artifacts than ACmapsZTE.
Dr
Paola Scifo
(Nuclear Medicine Dept, IRCCS San Raffaele Scientific Institute, Milan, Italy)
Dr
Maurizio Barbera
(Neuroradiology Unit, IRCCS Scientific Institute San Raffaele, Milan, Italy)
Dr
Annarita Savi
(Nuclear Medicine Dept, IRCCS San Raffaele Scientific Institute,Milan, Italy)
Dr
Federico Fallanca
(Nuclear Medicine Dept, IRCCS San Raffaele Scientific Institute, Milan, Italy)
Dr
Ilaria Neri
(Nuclear Medicine Dept, IRCCS San Raffaele Scientific Institute, Milan, Italy)
Dr
Valentino Bettinardi
(Nuclear Medicine Dept, IRCCS San Raffaele Scientific Institute, Milan, Italy)
Dr
Giovanna Gattuso
(Department of Medical Oncology and Hematology, Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, MIlan, Italy)
Dr
Maura Massimino
(Department of Medical Oncology and Hematology, Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
Dr
Paolo Verdelio
(Unit of Bioinformatics and Biostatistics, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
Dr
Sara Pizzamiglio
(Unit of Bioinformatics and Biostatistics, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
Prof.
Andrea Falini
(Neuroradiology Unit, IRCCS San Raffaele Scientific Institute)
Dr
Luigi Gianolli
(Nuclear Medicine Dept, IRCCS San Raffaele Scientific Institute, Milan, Italy)
Dr
Filippo Spreafico
(Department of Medical Oncology and Hematology, Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
Prof.
Maria Picchio
(Nuclear Medicine Dept, IRCCS San Raffaele Scientific Institute, Milan, Italy)
Dr
Cristina Baldoli
(Neuroradiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy)
